Email this article 
Post a Comment 
Estimation of transition doses for human glioblastoma, neuroblastoma and prostate cell lines using the linear-quadratic formalism
Abstract
Purpose: The introduction of stereotactic radiotherapy has raised concerns regarding the use of the linear-quadratic (LQ) model for predicting radiation response for large fractional doses. To partly address this issue, a transition dose D* below which the LQ model retains its predictive strength has been proposed. Estimates of D* which depends on the a, β, and D0 parameters are much lower than fractional doses typically encountered in stereotactic radiotherapy. D0, often referred to as the final slope of the cell survival curve, is thought to be constant. In vitro cell survival curves generally extend over the first few logs of cell killing, where D0-values derived from the multi-target formalism may be overestimated and can lead to low transition doses.
Methods: D0-values were calculated from first principles for each decade of cell killing, using experimentally-determined a and β parameters for 17 human glioblastoma, neuroblastoma, and prostate cell lines, and corresponding transition doses were derived.
Results: D0 was found to decrease exponentially with cell killing. Using D0-values at cell surviving fractions of the order of 10-10 yielded transition doses ~3-fold higher than those obtained from D0-values obtained from conventional approaches. D* was found to increase from 7.84 ± 0.56, 8.91 ± 1.20, and 6.55 ± 0.91 Gy to 26.84 ± 2.83, 23.95 ± 2.03, and 22.49 ± 2.31 Gy for the glioblastoma, neuroblastoma, and prostate cell lines, respectively.
Conclusion: These findings suggest that the linear-quadratic formalism might be valid for estimating the effect of stereotactic radiotherapy with fractional doses in excess of 20 Gy.
Keywords
Full Text:
PDFReferences
Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982;8:1981-97.
Withers HR. Biologic basis for altered fractionation schemes. Cancer 1985;55:2086-95.
Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62:679-94.
Fowler JF, Tomé WA, Fenwick JD, Mehta MP. A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys. 2004;60:1241-56.
Thames HD, Bentzen SM, Turesson I, et al. Time-dose factors in radiotherapy: a review of the human data. Radiother Oncol. 1990;19:219-35.
Jones B, Tan LT, Dale RG. Derivation of the optimum dose per fraction from the linear quadratic model. Br J Radiol. 1995;68:894-902.
Guerrero M, Li XA. Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol. 2004;49:4825-35.
Garcia LM, Wilkins DE, Raaphorst GP. Alpha/beta ratio: a dose range dependence study. Int J Radiat Oncol Bol Phys. 2007;67:587-93.
Kirkpatrick JP, Meyer JJ, Marks LB. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol. 2008;18:240-3.
Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:847-52.
Iwata H, Shibamoto Y, Murata R, et al. Estimation of errors associated with use of linear-quadratic formalism for evaluation of biologic equivalence between single and hypofractionated radiation doses: an in vitro study. Int J Radiat Oncol Biol Phys. 2009;75:482-8.
Shibamoto Y, Otsuka S, Iwata H, et al. Radiobiological evaluation of the radiation dose as used in high-precision radiotherapy: effect of prolonged delivery time and applicability of the linear-quadratic model. J Radiat Res. 2012;53:1-9.
Astrahan M. Some implications of linear-quadratic-linear radiation dose-response with regard to hypofractionation. Med Phys. 2008;35:4161-72.
Otsuka S, Shibamoto Y, Iwata H, et al. Compatibility of the linear-quadratic formalism and biologically effective dose concept to high-dose-per-fraction irradiation in a murine tumor. Int J Radiat Oncol Biol Phys. 2011;81:1538-43.
Iwata H, Matsufuji N, Toshito T, et al. Compatibility of the repairable-conditionally repairable, multi-target and linear-quadratic models in converting hypofractionated radiation doses to single doses. J Radiat Res. 2013;54:367-73.
Brenner DJ. The linear-quadratic model is an appropriate methodology for determining iso-effective doses at large doses per fraction. Semin Radiat Oncol. 2008;18:234-9.
Wulf J, Baier K, Mueller G, Flentje MP. Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol. 2005;77:83-7.
Milano MT, Katz AW, Schell MC, et al. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72:1516-22.
Takeda A, Sanuki N, Kunieda E, et al. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys. 2009;73(2):442-8.
Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non–small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011;81:1352-8.
Blomgren H, Lax I, Näslund I, Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator: clinical experience of the first thirty-one patients. Acta Oncol. 1995;34:861-70.
Seppenwoolde Y, Lebesque JV, de Jaeger K, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2003;55:724-35.
Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a Phase I study in medically inoperable Stage I non-small cell lung cancer. Chest 2003;124:1946-55.
Wada H, Takai Y, Nemoto K, Yamada S. Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors. Int J Radiat Oncol Biol Phys. 2004;58:1114-20.
McKenna FW, Ahmad S. Fitting techniques of cell survival curves in high-dose region for use in stereotactic body radiation therapy. Phys Med Biol. 2009;54:1593-608.
Ekstrand KE. The Hug−Kellerer equation as the universal cell survival curve. Phys Med Biol. 2010;55:N267-73.
Fowler JF. Linear quadratics is alive and well: in regard to Park et al. (Int J Radiat Oncol Biol Phys 2008;70:847-852). Int J Radiat Oncol Biol Phys. 2008;72:957; author reply 958.
Weichselbaum RR, Nove J, Little JB. X-ray sensitivity of human tumor cells in vitro. Int J Radiat Biol. 1980;6:437-40.
Jirtle RL, Michalopoulos G, McLain JR, Crowley J. Transplantation system for determining clonogenic survival of parenchymal hepatocytes exposed to ionizing radiation. Cancer Res. 1981;41:3512-8.
Fertil B, Malaise EP. Intrinsic radiosensitivity of human cell lines is correlated with radiosensitivity of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys. 1985;11:1699-707.
Malaise EP, Fertil B, Deschavanne PJ, et al. Initial slope of radiation survival curves is characteristic of the origin of primary and established cultures of human tumor cells and fibroblasts. Radiat Res. 1987;111:319-33.
Suit HD, Zietman A, Tomkinson K, et al. Radiation response of xenografts of a human squamous cell carcinoma and a glioblastoma multiforme: a progress report. Int J Radiat Oncol Biol Phys. 1990;18:365-73.
Gerweck LE, Zaidi ST, Zietman A. Multivariate determinants of radiocurability I: prediction of single fraction tumor control doses. Int J Radiat Oncol Biol Phys. 1994;29:57-66.
Taghian A, DuBois W, Budach W, et al. In vivo radiation sensitivity of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1995;32:99-104.
Vávrová J, Mareková-Řezáčová M, Vokurková D, et al. Caffeine induces a second wave of apoptosis after low dose-rate gamma radiation of HL-60 cells. Radiat Environ Biophys. 2003;42:193-9.
Akudugu JM, Slabbert JP, Serafin A, Böhm L. Frequency of radiation-induced micronuclei in neuronal cells does not correlate with clonogenic survival. Radiat Res. 2000;153:62-7.
Akudugu JM, Theron T, Serafin AM, Böhm L. Influence of DNA double‐strand break rejoining on clonogenic survival and micronucleus yield in human cell lines. Int J Radiat Biol. 2004;80:93-104.
Serafin A, Akudugu JM, Böhm L. Studies on the influence of DNA repair on radiosensitivity in prostate cell lines. Urol Res. 2003;31:227-31.
Hall EJ. Radiobiology for the radiologist. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2000.
Weininger J, Guichard M, Joly AM, et al. Radiosensitivity and growth parameters in vitro of three human melanoma strains. Int J Radiat Biol. 1978;34:285-290.
Malaise EP, Fertil B, Chavaudra N, Guichard M. Distribution of radiation sensitivities for human tumor cells of specific histological types: comparison of in vitro to in vivo data. Int J Radiat Oncol Bol Phys. 1986;12:617-24.
Marchese MJ, Zaider M, Hall EJ. Potentially lethal damage repair in human cells. Radiother Oncol. 1987;9:57-65.
Chavaudra N, Halimi M, Parmentier C, et al. The initial slope of human tumor cell survival curves: its modification by the oxic cell sensitizer β-arabinofuranosyladenine. Int J Radiat Oncol Biol Phys. 1989;16:1261-71.
Nahum AE, Movsas B, Horwitz EM, et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys. 2003;57:391-401.
DOI: http://dx.doi.org/10.14319/ijcto.33.11
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)
© International Journal of Cancer Therapy and Oncology (IJCTO)
To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.
Number of visits since October, 2013